Literature DB >> 9849986

Epidemiology and outcome of osteomyelitis in the era of sequential intravenous-oral therapy.

A Karwowska1, H D Davies, T Jadavji.   

Abstract

BACKGROUND: There has been little recent information on the epidemiology and outcome of childhood osteomyelitis since the era of sequential intravenous-oral antibiotic therapy.
METHODS: Retrospective chart review.
OBJECTIVE: To review the recent experience and outcome of osteomyelitis in children.
RESULTS: Between 1984 and 1996 we identified 146 patients with osteomyelitis. Decreased limb use and fever were the most common presenting symptoms, and tenderness was the most common sign. Staphylococcus aureus was the most common causative organism, and Haemophilus influenzae was not identified after 1990. Bone biopsies or aspirates were superior (83%) to blood cultures (32%) in yielding organisms. 99mTc bone scan was the most sensitive imaging test (94%). Lack of use of anti-teichoic acid titers and serum bactericidal titers did not adversely affect outcome. The median duration of intravenous antibiotic therapy was 11 days, with a median duration of total antibiotics of 38 days. Complications occurred in 6.6% of patients.
CONCLUSION: S. aureus remains the most important cause of osteomyelitis. Despite inconsistent use of tests for diagnosis and management and use of sequential intravenous-oral therapy, the overall outcome remains excellent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849986     DOI: 10.1097/00006454-199811000-00012

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

Review 1.  Acute hematogenous osteomyelitis in children: recognition and management.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

2.  Current data on acute haematogenous osteomyelitis in children in Southern Israel: epidemiology, microbiology, clinics and therapeutic consequences.

Authors:  Eugen Cohen; Karin Lifshitz; Yariv Fruchtman; Mark Eidelman; Eugene Leibovitz
Journal:  Int Orthop       Date:  2016-05-12       Impact factor: 3.075

Review 3.  US Evaluation of Juvenile Idiopathic Arthritis and Osteoarticular Infection.

Authors:  Jie C Nguyen; Kenneth S Lee; Mahesh M Thapa; Humberto G Rosas
Journal:  Radiographics       Date:  2017 Jul-Aug       Impact factor: 5.333

Review 4.  Proposed antithrombotic strategy for acute ischemic stroke with large-artery atherosclerosis: focus on patients with high-risk transient ischemic attack and mild-to-moderate stroke.

Authors:  Xiaowen Hou; Huisheng Chen
Journal:  Ann Transl Med       Date:  2020-01

5.  Musculoskeletal infection imaging: past, present, and future.

Authors:  Santiago Restrepo; Daniel Vargas; Roy Riascos; Hugo Cuellar
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 6.  Interaction of staphylococci with bone.

Authors:  John A Wright; Sean P Nair
Journal:  Int J Med Microbiol       Date:  2009-11-03       Impact factor: 3.473

7.  Fosfomycin for the initial treatment of acute haematogenous osteomyelitis.

Authors:  N Corti; F H Sennhauser; U G Stauffer; D Nadal
Journal:  Arch Dis Child       Date:  2003-06       Impact factor: 3.791

8.  Childhood osteomyelitis: imaging characteristics.

Authors:  Joost van Schuppen; Martine M A C van Doorn; Rick R van Rijn
Journal:  Insights Imaging       Date:  2012-08-10

9.  The efficacy of 16S ribosomal DNA sequencing in the diagnosis of bacteria from blood, bone and synovial fluid samples of children with musculoskeletal infections.

Authors:  S Hashavya; I Gross; A Michael-Gayego; N Simanovsky; R Lamdan
Journal:  J Child Orthop       Date:  2018-04-01       Impact factor: 1.548

Review 10.  Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review.

Authors:  Nicole Le Saux; Andrew Howard; Nicholas J Barrowman; Isabelle Gaboury; Margaret Sampson; David Moher
Journal:  BMC Infect Dis       Date:  2002-08-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.